After three and a half weeks of trial, a Middlesex County jury delivered a defense verdict for AstraZeneca in the first suit over its antipsychotic drug Seroquel to go to trial, Baker v. AstraZeneca Pharmaceuticals.
The jury deliberated seven hours Thursday before voting 7-to-1 that AZ’s Seroquel label provided adequate warning to the prescribing physician of the diabetes risk associated with the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
